Janus Kinase Inhibitors: all 1,428 studies that test it

Page 13 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.CompletedNCT03890770Phase 1
• Food Effect Study of CTP-543 in Healthy VolunteersCompletedNCT03880136Phase 1
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy MalesCompletedNCT03873415Phase 1
• Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy VolunteersCompletedNCT03868072Phase 1
• A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTSCompletedNCT03827668Phase 1
• Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and ChildrenCompletedNCT03826901Phase 1
• Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single-Dose of PF-06651600 in Healthy ParticipantsCompletedNCT03821493Phase 1
• Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy ParticipantsCompletedNCT03806101Phase 1
• Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic DisordersActive, not recruitingNCT03801434Phase 2
• Ruxolitinib Combined With Dexamethasone for HLHStatus unknownNCT03795909Phase 1/2
• Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different FormulationsCompletedNCT03765554Phase 1
• ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZCompletedNCT03762928Phase 1
• A Taste Assessment of BMS-986165 in Healthy ParticipantsCompletedNCT03751228Phase 1
• Multiple Dose Ethnobridging PK Study in Healthy SubjectsCompletedNCT03750565Phase 1
• Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy ParticipantsCompletedNCT03742336Phase 1
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male ParticipantsCompletedNCT03739788Phase 1
• Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical TrialStatus unknownNCT03738956Phase 2/3
• Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic ArthritisCompletedNCT03736161Phase 3
• A Study of AZD4205 in Healthy Adult SubjectsCompletedNCT03728023Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic ArthritisActive, not recruitingNCT03725007Phase 1
• Effect of Baricitinib Treatment on Peripheral Bone in RAStatus unknownNCT03701789Phase 3
• Ruxolitinib and Steroid As First Line Therapy for Acute GVHDTerminatedNCT03701698Phase 2
• Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm DysfunctionActive, not recruitingNCT03681275Phase 2
• A Phase II Study in Patients With Moderate to Severe Active Crohn's DiseaseCompletedNCT03677648Phase 2
• Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)Active, not recruitingNCT03674047Phase 2
• Itacitinib in Treating Patients With Refractory Metastatic/Advanced SarcomasTerminatedNCT03670069Phase 1
• A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female SubjectsCompletedNCT03662516Phase 1
• A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT03661138Phase 3
• An Investigational Study of Experimental Medication BMS-986165 in Healthy ParticipantsCompletedNCT03660436Phase 1
• A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy VolunteersCompletedNCT03656952Phase 1
• Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast CancerCompletedNCT03654547Phase 1
• A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy VolunteersCompletedNCT03647670Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic DermatitisCompletedNCT03646604Phase 1
• Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)Active, not recruitingNCT03645824Phase 2
• Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842.CompletedNCT03637790Phase 1
• Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.CompletedNCT03634345Phase 1
• A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative ColitisWithdrawnNCT03627052Phase 2
• Ruxolitinib Plus LVP in Patients With R/R ETP-ALLStatus unknownNCT03613428Phase 1/2
• Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase InhibitorsActive, not recruitingNCT03610971Phase 2
• A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)CompletedNCT03608241Phase 1
• Pacritinib in Relapsed/Refractory Lymphoproliferative DisordersTerminatedNCT03601819Phase 1
• Tofacitinib Combined With Chidamide in R/R ENKTCLStatus unknownNCT03598959Phase 2
• The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative NeoplasmStatus unknownNCT03558607Phase 1/2
• Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging StudyCompletedNCT03555617Phase 1
• An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram EffectsCompletedNCT03541564Phase 1
• Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in BangladeshStatus unknownNCT03504072Phase 4
• Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese SubjectsCompletedNCT03497273Phase 1
• Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung CancerCompletedNCT03450330Phase 1/2
• Extended Access of Momelotinib in Adults With MyelofibrosisActive, not recruitingNCT03441113Phase 2
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic DermatitisCompletedNCT03422822Phase 3
• An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male ParticipantsCompletedNCT03419910Phase 1
• TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male SubjectsCompletedNCT03408470Phase 1
• A Study to Investigate BMS-986165 and Methotrexate in Healthy Male PatientsCompletedNCT03402087Phase 1
• A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and MoxifloxacinCompletedNCT03386279Phase 1
• Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With MyelofibrosisTerminatedNCT03386214Phase 1
• Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of MyelofibrosisTerminatedNCT03373877Phase 1
• A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433Active, not recruitingNCT03345823Phase 3
• Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.TerminatedNCT03325296Phase 2
• An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.TerminatedNCT03320876Phase 2
• GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseTerminatedNCT03320642Phase 1
• Ruxolitinib + Allogeneic Stem Cell Transplantation in AMLActive, not recruitingNCT03286530Phase 2
• Effect of Ruxolitinib on Tumor Infiltrating Myeloid CellsWithdrawnNCT03274778Not applicable
• The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female PatientsCompletedNCT03262727Phase 1
• A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic DermatitisCompletedNCT03257644Phase 1
• Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) PatientsCompletedNCT03254966Phase 2
• A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet FormulationCompletedNCT03254784Phase 1
• Absorption, Metabolism, Excretion and Absolute BioavailabilityCompletedNCT03250039Phase 1
• Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy VolunteersCompletedNCT03236493Phase 1
• Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy VolunteersCompletedNCT03232905Phase 1
• A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisActive, not recruitingNCT03165734Phase 3
• Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)TerminatedNCT03159936Early Phase 1
• Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
• A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing SpondylitisCompletedNCT03117270Phase 2
• A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic ArthritisCompletedNCT03101670Phase 2
• A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With MyelofibrosisActive, not recruitingNCT03069326Phase 2
• Effect of BMS-986165 on the Pharmacokinetics of RosuvastatinCompletedNCT03044873Phase 1
• Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast CancerCompletedNCT03012230Phase 1
• A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)Active, not recruitingNCT03006068Phase 3
• Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male ParticipantsCompletedNCT03004768Phase 1
• Study of Tofacitinib in Refractory DermatomyositisCompletedNCT03002649Phase 1
• Ruxolitinib for Steroid-refractory GVHDCompletedNCT02997280Phase 2
• A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CMLWithdrawnNCT02973711Phase 1/2
• The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second LineTerminatedNCT02962388Phase 2/3
• Open-Label Crossover Study Comparing CTP-543 to Jakafi®CompletedNCT02960945Phase 1
• An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibActive, not recruitingNCT02955940Phase 2
• An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerCompletedNCT02917993Phase 1/2
• Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With MyelofibrosisCompletedNCT02917096Phase 1
• Filgotinib in Long-Term Extension Study of Adults With Ulcerative ColitisCompletedNCT02914535Phase 3
• Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia PatientsStatus unknownNCT02912754Phase 1/2
• Relieving Chronic Itch: Oral MedicationWithdrawnNCT02909569Phase 2
• Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy SubjectsStatus unknownNCT02892370Phase 1
• TD-1473 for Active Ulcerative Colitis (UC)CompletedNCT02818686Phase 1
• Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy SubjectsCompletedNCT02807116Phase 1
• PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy SubjectsCompletedNCT02807077Phase 1
• To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy SubjectsCompletedNCT02807051Phase 1
• PTCy and Ruxolitinib GVHD Prophylaxis in MyelofibrosisCompletedNCT02806375Phase 1/2
• Investigate Absorption, Metabolism, Excretion, and Mass Balance of PacritinibCompletedNCT02803762Phase 1
• Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy SubjectsCompletedNCT02777008Phase 1
• Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy SubjectsCompletedNCT02765724Phase 1

← Janus Kinase Inhibitors overview